Collagen human

Bornstein and Traub Type I, acid soluble, powder, ~95% (SDS-PAGE)

CAS Number:
EC Number:
MDL number:

Quality Level

biological source



~95% (SDS-PAGE)




cell culture | stem cell: suitable


aqueous acid: ≤5 mg/mL

UniProt accession no.

storage temp.


Gene Information

human ... COL1A2(1278)

Looking for similar products? Visit Product Comparison Guide

General description

Collagen type 1 alpha 2 (COL1A2) encodes pro-alpha2 chain and is a component of heterodimer, type 1 collagen fiber. It is mapped to human chromosome 7q21.3. COL1A2 associates with COL1A1 in the ratio 1:2 and undergoes posttranslational modification to form mature type I collagen fibre.
Collagen is classified into a number of structurally and genetically distinct types. We use the nomenclature proposed by Bornstein and Traub. Do not confuse Sigma type designations with recognized collagen classification types.


Human collagen has been used:
  • as a component of extracellular matrix in the chemotaxis assay of the rat adipose-derived stem cells
  • in adhesion assay of the adult retinal pigmented epithelium-19 (ARPE-19) cell line
  • in the glycation aggregation and adsorption studies as a model system for arthritis

Collagen type I may be used in research of Idiopathic pulmonary fibrosis (IPF). Robust expression of collagen-type I is one distinctive feature of IPF. Additionally, collagen-type I has been used in studies on the effect of endoplasmic reticulum (ER) stress from IPF on myofibroblastic differentiation of lung fibroblasts. Collagen-type I soluble in acidic solution produces three dimensional scaffolding useful in bioengineering and cell culture applications where biomaterials are needed to replace native collagen extracellular matrices.

Collagen Type I has been used as a scaffold for the growth in vitro of stem cells in a wide variety of biomaterial engineering studies.


1 mg in glass bottle

Biochem/physiol Actions

Collagen type 1 alpha 2 (COL1A2) is crucial for bone formation, cartilage and blood vessels. Imbalance in COL1A2 may be the cause for dental fluorosis. Missense mutations involving glycine substitutions in the COL1A2 gene alters the collagen triple helix structure decreasing its stability and is implicated in osteogenesis imperfecta. Mutations near the splice site of COL1A2 gene results in exon skipping and is associated with Ehlers-Danlos Syndrome. An insertion or deletion polymorphism in the COL1A2 gene impairs its interaction with microRNA and modulates the bone mineral density resulting in high susceptibility to osteoporosis.

Preparation Note

Prepared from human skin by modification of Gallop, P.M.

Personal Protective Equipment

dust mask type N95 (US),Eyeshields,Gloves


NONH for all modes of transport

WGK Germany


Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificate of Analysis

Certificate of Origin

Aggregation as a consequence of glycation: insight into the pathogenesis of arthritis
Shamsi A, et al.
European Biophysics Journal, 45(6), 523-534 (2016)
Tissue engraftment of hypoxic-preconditioned adipose-derived stem cells improves flap viability
Hollenbeck SC, et al.
Wound Repair and Regeneration, 20(6), 872-878 (2012)
An insertion/deletion polymorphism within the 3'-untranslated region of COL1A2 confers susceptibility to osteoporosis
Jiang ZS and Hao ZH
Molecular Medicine Reports, 14(5), 4415-4421 (2016)
Regulation of type I collagen genes expression
Rossert J, et al.
Nephrology, Dialysis, and Transplantation, 15(6), 66-68 (2000)
Gene expression of collagen type I alpha 2 and its relationship with dental fluorosis.
Gastelbondo-Pastrana B, et al.
Journal of Oral Research, 7(6), 172-175 (2018)

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.